Evidence map›Paper›PMID 30428836›Full record

Trial reportBMC geriatrics2018

Quality of life and paracetamol in advanced dementia (Q-PID): protocol of a randomised double-blind placebo-controlled crossover trial.

Paulien H van Dam, Wilco P Achterberg, Jacobijn Gussekloo, Bettina S Husebo, Monique A A Caljouw

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC geriatrics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Quality of life in people with dementia living in nursing homes: validation of an eight-item version of the QUALIDEM for intensive longitudinal assessment.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Paulien H van DamDepartment of Public Health and Primary Care, Leiden University Medical Center, P.O. Box 9600, 2300 RC, Leiden, The Netherlands. p.h.van_dam@lumc.nl.ORCID 0000-0003-1066-2457
Wilco P AchterbergDepartment of Public Health and Primary Care, Leiden University Medical Center, P.O. Box 9600, 2300 RC, Leiden, The Netherlands.
Jacobijn GusseklooDepartment of Public Health and Primary Care, Leiden University Medical Center, P.O. Box 9600, 2300 RC, Leiden, The Netherlands.
Bettina S HuseboDepartment of Global Public Health and Primary Care, Centre for Elderly - and Nursing Home Medicine, University of Bergen, Kalfarveien 31, N-5020, Bergen, Norway.
Monique A A CaljouwDepartment of Public Health and Primary Care, Leiden University Medical Center, P.O. Box 9600, 2300 RC, Leiden, The Netherlands.
Leiden University Medical Center · NLBergen Kommune · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNo proven effective interventions on quality of life (QoL) are available for persons with dementia in a long-term care facility (LTCF). However, several interventions are effective in diminishing mediators of QoL (i.e. challenging behaviour, depressed mood, sleeping disorders), including pain treatment. Un(der)diagnosed and un(der)treated pain is a serious and frequent problem in persons with dementia. Also, although pain is difficult to assess in this group, the impact on QoL is probably considerable. There is evidence that pain has a negative impact on behaviour, mood, functioning and social participation, and benefit may be derived from use of paracetamol. Therefore, in LTCF residents with advanced dementia, this study aims to evaluate the effect of scheduled pain treatment with paracetamol on QoL, neuropsychiatric symptoms, ADL function, pain, care dependency, and (change in) use of psychotropic and pain medication.

methodsThis randomised, double-blind, placebo-controlled crossover trial will include 95 patients with: 1) age ≥ 65 years, 2) advanced dementia (Reisberg Global Deterioration Scale 5-7), and 3) QUALIDEM score ≤ 70. Exclusion criteria are the regular use of pain treatment, allergies to the study drugs, severe liver insufficiency or disease, use of > 4 units of alcohol/day, weight < 50 kg, and/or concomitant use of flucloxacillin. The two treatment periods of six weeks each (paracetamol and corresponding placebo) will be separated by a washout period of seven days. Primary outcome is effect on QoL (QUALIDEM and DS-DAT) and secondary outcome is effect on neuropsychiatric symptoms, ADL function, pain, care dependency, and (change in) use of psychotropic and pain medication (all compared to baseline). DISCUSSION: If regular treatment with paracetamol proves to be beneficial for QoL, this could have major implications for daily practice in long-term care. Information from this study may help professionals in their decision making regarding the prescription of pain medication to improve the QoL of persons with dementia and a low QoL.

trial registrationThe trial was registered on the Netherlands Trial Register ( NTR6766 ); Trial registration date: 20th October, 2017.

Indexed as

AcetaminophenAgedAnalgesics, Non-NarcoticCross-Over StudiesDementiaDepressionDouble-Blind MethodFemaleFollow-Up StudiesHumansLong-Term CareMaleNetherlandsNursing HomesPainPain ManagementAcetaminophenAnalgesics, Non-NarcoticDementiaNursing homeParacetamolQUALIDEMQuality of life

Identifiers

PMID30428836
PMCPMC6234644
OpenAlexW2900603071

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.